What is this summary about?This summary describes an article published in the medical journal eJHaem in September 2024. The article reports a real-world study in which the authors looked at how therapies worked in everyday settings by using the Center for International Blood and Marrow Transplant Research® or CIBMTR® Database to collect information on individuals with diffuse large B-cell lymphoma or DLBCL. The study included 16 adults with DLBCL in the United States who had accepted 2 therapies that target different regions of the same protein, which is called CD19, on cancer cells. All individuals received loncastuximab tesirine, known as Lonca, before receiving CAR-T therapy. The authors studied how both therapies worked in all individuals and in 2 smaller Lonca groups: one group who was given Lonca as bridging therapy and another group who received Lonca as the last cancer therapy before CAR-T therapy.What were the results?Overall, 10 of 16 (63%) individuals with DLBCL who received Lonca before CAR-T therapy had their cancer either completely disappear or get smaller after therapy. This happened in the overall group and the 2 smaller Lonca groups, who received Lonca as a bridging therapy or as the last therapy before CAR-T therapy. Investigators estimated that 1 year after CAR-T therapy, 33% of individuals would still be alive, and 28% would be alive without their disease worsening.What do the results mean?Treating individuals with Lonca does not stop individuals from responding to CAR-T therapy in the future. The authors think that this may be possible because the therapies target different regions of the CD19 protein on the cancer cell surface.[Box: see text].